Ligand id: 1234

Name: ranitidine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ranitidine

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 108.88
Molecular weight 314.14
XLogP 1.28
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Ranitidine is used in the treatment of gastic ulcers, where blocking of H2 receptors reduces gastric acid secretion and ameliorates disease symptoms. At the beginning of April 2020 the FDA withdrew marketing authorisation for all ranitidine products, after excess levels of the hepatotoxic and carcinogenic chemical N-nitrosodimethylamine (NDMA) were detected in ranitidine medications. Mylan had voluntarily recalled prescription nizatidine capsules for the same reason in January 2020.
Mechanism Of Action and Pharmacodynamic Effects
Competitive inhibition of H2 receptors on parietal cells leads to supression of gastric acid secretion.
External links